Cardiogen Peptide

$55.00

Description

Cardiogen Peptide

Cardiogen (also known as CGP or H-Tyr-Ala-Glu-Asp-Gly-Pro-Arg-OH) is a synthetic tetrapeptide bioregulator developed primarily for research into cardiovascular health. It belongs to a class of short-chain peptides derived from research by Russian scientists (e.g., Vladimir Khavinson’s group), often categorized as “cytomedins” or tissue-specific bioregulators. These peptides are designed to mimic natural regulatory signals in the body, targeting specific organs like the heart.

Key Facts:

Molecular Formula: C₃₃H₅₁N₉O₁₂
Molecular Weight: ~789.8 g/mol
Structure: A linear tetrapeptide sequence (Ala-Glu-Asp-Arg), sometimes listed with additional residues in variants.
Origin: Extracted or synthesized based on peptides from calf heart tissue; not a naturally occurring hormone but a lab-engineered analog.

Purported Mechanism of Action

Cardiogen is researched for its potential to:

Regulate gene expression in cardiomyocytes (heart muscle cells) by influencing transcription factors, promoting repair and normalization of heart tissue.
Activate telomerase and support telomere length, which may aid cellular rejuvenation.
Reduce fibrosis and inflammation in cardiac tissue, potentially improving contractility and vascular function.
Modulate apoptosis (programmed cell death) in damaged heart cells.

Evidence Base (from available studies):

Preclinical Studies: Russian research (e.g., Khavinson et al., 2000s–2010s) in animal models (rats, rabbits) showed Cardiogen normalized ECG readings, reduced myocardial infarction damage, and improved heart function post-ischemia. For example, a 2011 study in Bulletin of Experimental Biology and Medicine reported 20–30% reduction in infarct size.
Human Data: Limited to anecdotal reports and small-scale trials in Russia. No large-scale FDA/EMA-approved RCTs. A 2014 review in Advances in Gerontology suggested benefits for age-related cardiac decline.
PubMed/Research Citations: Search terms like “Cardiogen peptide” yield ~20 papers, mostly from Russian journals (e.g., PMID: 21449447). Western validation is sparse.

Study Type	Key Findings	Limitations
Animal (Rat MI model)	↓ Infarct size by 25%, ↑ ejection fraction	Small n=20–50, no long-term follow-up
In Vitro (Cardiomyocytes)	↑ Proliferation by 15–20%, ↓ Oxidative stress	Not human cells
Human (Observational, n=50 elderly)	Improved ECG in 60%	No placebo control, self-reported

Potential Uses (Research Contexts)

Cardiovascular Repair: Post-MI recovery, heart failure, arrhythmias.
Anti-Aging: Heart tissue rejuvenation.
Hypertension/Atherosclerosis: Vascular normalization.
Often stacked with other peptides like Ventfort (vessels) or Chelohart (heart).

Dosage in Research Protocols (not medical advice):

Typical: 100–200 mcg/day subcutaneously or intramuscularly for 10–20 days, cycled 2–3x/year.
Purity: Lab-sourced at >98% via HPLC.

Availability and Legality

Sold As: Research chemical (not for human consumption) from peptide vendors (e.g., CosmicNootropic, Peptide Sciences). Prices: $30–60 for 10–20mg vial.
Status:

Region	Legal Status
USA	Research-only; not FDA-approved drug/supplement. Schedule not controlled.
EU	Similar; novel food restrictions may apply.
Russia	Registered as dietary supplement (e.g., “Cardiogen” by Imedis).

Risks/Warnings: Potential side effects include injection-site reactions, unknown long-term safety, contamination in unregulated sources. Contraindicated in pregnancy, cancer (telomerase activation concern). Always third-party test purity (e.g., Janoshik).

Comparison to Similar Peptides

Peptide	Target	Key Difference
Cardiogen	Heart muscle	Shortest chain, telomerase focus
Chelohart	Heart extract	Broader extract, less specific
Ventfort	Blood vessels	Vascular vs. myocardial
Epitalon	General anti-aging	Pineal gland, systemic telomeres

Bottom Line: Cardiogen shows promise in niche research for heart repair but lacks robust clinical evidence. Consult a physician before any use; it’s experimental. For deeper dives, check primary sources like Khavinson’s reviews on PubMed or ResearchGate. If you have a specific question (e.g., sourcing, protocols), let me know!

Delivery Details

2-3 days from the time of purchase to all locations

Order now and enjoy great discounts! We deliver top-quality peptide products straight to you. Fast, reliable, and discreet service. Delivery hours: 10 AM–8 PM daily. Don’t miss out

Cardiogen Peptide Research

Core Research Themes

Cardioprotection: Post-ischemia repair, anti-fibrosis.
Anti-Aging: Telomere elongation, gene expression normalization.
Regenerative Effects: Cardiomyocyte proliferation, apoptosis modulation.

Publication Stats (as of 2024):

~50 papers (mostly Russian journals).
PubMed: 15+ hits for "Cardiogen" or "кардиоген".
Citations: Primarily Khavinson V.Kh. et al. (St. Petersburg Institute of Bioregulation).

Key Studies and Findings

Year	Study	Model	Key Results	PMID/DOI
2004	Khavinson et al. Bull Exp Biol Med	Rat MI model (n=40)	↓ Infarct size 28%, ↑ Survival 35%, normalized ECG	PMID: 15592594
2007	Khavinson et al. Adv Gerontol	Aged rats	↑ Myocardial contractility 22%, ↓ Fibrosis markers (collagen I/III)	PMID: 18265320
2011	Bondarenko et al. Bull Exp Biol Med	Rabbit ischemia-reperfusion	↓ Arrhythmia 40%, ↑ Coronary flow 18%	PMID: 21449447
2014	Khavinson et al. Adv Gerontol	Human elderly (n=42, open-label)	Improved ECHO parameters in 62%; ↑ Ejection fraction ~5%	DOI: 10.1134/S207905701402005X
2016	Mironova et al. Morfologiia	Rat cardiomyopathy	Normalized cardiomyocyte ultrastructure; ↑ Telomerase activity 15%	Russian journal (no PMID)
2019	Khavinson review Biogerontology	Meta-analysis (10 studies)	Epigenetic effects: ↑ 17 heart-specific genes (e.g., MYH6, ACTC1)	PMID: 30868479
2022	Ryzhak et al. Int J Mol Sci	In vitro cardiomyocytes + doxorubicin	↓ Apoptosis 30%, ↑ Viability via PI3K/Akt pathway	PMID: 35269700

Evidence Hierarchy

Strong (Preclinical Consistent): Cardioprotection in ischemia models (n=10+ studies).

Moderate: Anti-fibrotic, telomerase effects (in vitro/animal).

Weak: Human data (small, non-randomized; e.g., n<100 total).

None: Large RCTs, Western pharma trials.

Mechanisms (Supported by Research)

Epigenetic Regulation: Binds DNA promoters → ↑ Expression of cardiac genes (e.g., GATA4, NKX2.5). Confirmed via qPCR/ChIP in 2019 review.
Telomerase Activation: ↑ hTERT mRNA 12–20% (2016 study); indirect anti-aging via telomere protection.
Signaling Pathways: Activates Akt/ERK, inhibits TGF-β fibrosis (2022 in vitro).
No Hormonal Effects: Does not alter cAMP/steroids significantly.

Dose-Response from Studies:

Model	Dose	Duration	Effect Size
Rat	10–50 mcg/kg SC	10 days	Optimal
Human	100–200 mcg/day	10–20 days	Anecdotal max

Research Gaps & Criticisms

Replication: 95% Russian-led; limited independent verification.
Controls: Few double-blind trials; publication bias possible.
Toxicity: No carcinogenicity (telomerase concern theoretical); LD50 >500 mg/kg in rodents.
Western Interest: Minimal; peptides like this face regulatory hurdles (e.g., FDA orphan drug path unlikely).

Ongoing/Recent Developments

2023–2024: Russian trials combining Cardiogen + stem cells for CHF (preliminary, ClinicalTrials.ru).
Patents: RU 2,XXX,XXX (Khavinson) for synthesis/use.
Related Research: Analog peptides (e.g., CHG) in PubMed for broader bioregulators.

Access Research

Free Sources: PubMed, ResearchGate (Khavinson profile: 500+ pubs), Google Scholar "Cardiogen Khavinson".
Paywalled: Springer, Pleiades Publishing (Russian journals).
Books: "Peptides and Ageing" (Khavinson, 2002); "Gerontological Aspects of Genome Peptide Regulation" (2009).